Accelrys and Pfizer Extend Agreement for Global Deployment of Scientific Innovation Lifecycle Management Software

   Accelrys and Pfizer Extend Agreement for Global Deployment of Scientific
                   Innovation Lifecycle Management Software

Three-year contract offers Pfizer researchers access to software for
accelerating drug development and advancing innovation

PR Newswire

SAN DIEGO, May 7, 2013

SAN DIEGO, May 7, 2013 /PRNewswire/ --Accelrys, Inc. (NASDAQ: ACCL), a
leading provider of scientific innovation lifecycle management software,
announced today that Pfizer, Inc. (NYSE: PFE) has signed a three-year contract
with Accelrys, extending the companies' long-standing strategic partnership.
The agreement continues the global deployment of the Accelrys Enterprise
Platform, Pipeline Pilot, Cheminformatics Suite and Modeling & Simulation
software to Pfizer researchers worldwide.


The scientifically aware Accelrys Enterprise Platform offers access to broad
scientific informatics solutions across different domains while simplifying
integration into existing IT environments. The Pipeline Pilot scientific
workflow authoring application enables scientific services that automate the
process of accessing, analyzing and reporting scientific data for sharing
across the scientific community. Leveraging the Accelrys Cheminformatics
Suite, scientists can register, search, mine, analyze and report on chemical
structures and reactions, chemically modified sequences and associated
information such as inventory, assay and analytical results. Accelrys Modeling
and Simulation software accelerates collaborative research and development of
innovative health care treatments through the use of predictive science.

Accelrys President and Chief Executive Officer Max Carnecchia described the
profound challenges that are requiring pharmaceutical companies to transform
their businesses to remain competitive, saying, "From externalization to cost
pressures to regulatory compliance, today's industry trends are making it more
difficult for pharmaceutical organizations to deliver innovative products to
market quickly and cost-effectively. As Pfizer well knows, overcoming these
challenges demands both disease area and technology expertise. Accelrys'
integrated technology solutions ― built with deep scientific understanding ―
are helping valued customers like Pfizer grow their businesses to meet the
demands of today and tomorrow."

About Accelrys, Inc.
Accelrys (NASDAQ:ACCL), a leading provider of scientific innovation lifecycle
management software, supports industries and organizations that rely on
scientific innovation to differentiate themselves. The industry-leading
Accelrys Enterprise Platform provides a broad, flexible scientific solution
optimized to integrate the diversity of science, experimental processes and
information requirements across the research, development, process scale-up
and early manufacturing phases of product development. By incorporating
capabilities in applications for modeling and simulation, enterprise lab
management, workflow and automation, and data management and informatics,
Accelrys enables scientific innovators to access, organize, analyze and share
data in unprecedented ways, ultimately enhancing innovation, improving
productivity and compliance, reducing costs and speeding time from lab to

Accelrys solutions are used by more than 1,300 companies in the
pharmaceutical, biotechnology, energy, chemicals, aerospace, consumer packaged
goods and industrial products industries. Headquartered in San Diego, Calif.,
Accelrys employs more than 200 full-time PhD scientists. For more information
about Accelrys, visit

Related Links
Accelrys Website
Follow Accelrys on Twitter
Friend Accelrys on Facebook
Accelrys' YouTube Channel
Connect with Accelrys on LinkedIn

SOURCE Accelrys, Inc.

Contact: Racepoint Group, For Accelrys, Susan Thomas, 619-540-9195 /
Press spacebar to pause and continue. Press esc to stop.